NCT02026921View on ClinicalTrials.gov

A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

December 31, 2008

Conditions
Ovarian Epithelial Cancer Recurrent
Interventions
DRUG

Carboplatin

Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops

DRUG

Docetaxel

75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.

Trial Locations (4)

2730

Herlev University Hospital, Copenhagen

9000

Aalborg University Hospital, Aalborg

Unknown

Tampere University Hospital, Tampere

0310

Norwegian Radium Hospital, Oslo

All Listed Sponsors
lead

Nordic Society of Gynaecological Oncology - Clinical Trials Unit

OTHER

NCT02026921 - A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer | Biotech Hunter | Biotech Hunter